Exploring the interaction between CXCL10/CXCR3 and ferroptosis provides an experimental basis for using the CXCL10/CXCR3 axis as a therapeutic target for the treatment of ROP ophthalmopathy. This evidence concerns the gene CXCR3 and retinopathy of prematurity.